|1.||Blanchette, Christopher M: 7 articles (01/2011 - 06/2007)|
|2.||Dalal, Anand A: 6 articles (06/2012 - 01/2009)|
|3.||Rutten-van Mölken, Maureen P M H: 5 articles (04/2012 - 01/2003)|
|4.||Stanford, Richard H: 5 articles (01/2009 - 03/2005)|
|5.||Oostenbrink, Jan B: 4 articles (06/2007 - 01/2003)|
|6.||Barnes, Peter J: 4 articles (10/2005 - 09/2002)|
|7.||Rodrigo, Gustavo J: 4 articles (06/2003 - 06/2002)|
|8.||van Noord, J A: 4 articles (04/2002 - 04/2000)|
|9.||Lee, Todd A: 3 articles (01/2014 - 09/2008)|
|10.||Tamai, Ikumi: 3 articles (09/2013 - 02/2010)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
01/29/1996 - "These data suggest that the availability of a high-dose ipratropium bromide solution offers a safe and effective means of producing prolonged bronchodilation in patients with COPD."
01/01/2000 - "[Is nebulized ipratropium bromide effective in the treatment of exacerbations of chronic obstructive pulmonary disease?]."
05/01/1989 - "Inhaled ipratropium bromide (IPR) is effective in the management of COPD. "
11/14/1986 - "Single-agent studies have shown ipratropium to be both safe and effective in COPD. "
01/29/1996 - "These results show that ipratropium bromide, given by nebulization, is safe and effective in the outpatient treatment of COPD."
|2.||Asthma (Bronchial Asthma)
07/01/1995 - "To determine whether inhaled ipratropium bromide provides an additive, clinically important improvement in children with acute asthma who are being treated with beta 2-agonists. "
06/01/2000 - "We designed a larger, double-blind, randomized, prospective trial to test our hypothesis that patients with acute asthma given combination high dose therapy with ipratropium bromide (IB) and beta(2)-agonists will have greater improvement in pulmonary function and fewer hospital admissions than those given beta(2)-agonists alone. "
06/01/2003 - "High and repetitive doses of ipratropium bromide in combination with beta(2)-agonists are indicated as first line treatment of severe acute asthma. "
06/01/2002 - "(2) The use of single-dose protocols of ipratropium bromide with beta(2)-agonist treatment produced, particularly in children with more severe acute asthma, a modest improvement in pulmonary function without reduction in hospital admissions; in adults, the data showed a similar increase in pulmonary function with an approximately 35% reduction in the hospital admission rate. "
01/01/1992 - "Therefore, ipratropium bromide offers bronchodilation and protection against a variety of stimuli and should more often be considered as an effective and safe drug for asthma treatment."
04/01/1987 - "It is concluded that intranasal ipratropium is effective in the treatment of watery rhinorrhea in perennial nonallergic rhinitis and that 320 micrograms a day is sufficient in most patients."
04/01/1987 - "The aim of the present study was to test the efficacy of the topically active cholinoceptor antagonist, ipratropium, in the treatment of rhinorrhea in perennial nonallergic rhinitis, with special reference to identification of subgroups of responders and increased efficacy from high-dose therapy. "
01/01/2014 - "A nasal vasoconstrictor can be added for short-term treatment, and an ipratropium spray can be beneficial in perennial non-allergic rhinitis, when watery secretion is the dominant symptom. "
06/01/1992 - "We speculate that ipratropium bromide may prove beneficial for the treatment of rhinorrhea in perennial rhinitis. "
05/01/1995 - "The purpose of the present trial was to study the safety and efficacy of a new isotonic aqueous ipratropium bromide nasal spray pump, specifically in patients with perennial nonallergic rhinitis. "
01/01/1998 - "The highest atrovent efficacy was recorded in patients with chronic bronchitis of smokers and chronic bronchitis in tracheobronchial diskinesia. "
01/29/1996 - "Ipratropium bromide has become primary therapy for the treatment of adults with chronic bronchitis, but its use in children has been limited. "
05/01/1994 - "Whether nebulized ipratropium bromide is of benefit to mechanically ventilated patients with chronic bronchitis is not well defined. "
01/01/1985 - "We conclude that ipratropium bromide should be inhaled in high doses (0.2 mg) by hypersecretory patients with chronic bronchitis to improve mucociliary transport."
01/01/1985 - "Influence of 0.2 mg ipratropium bromide on mucociliary clearance in patients with chronic bronchitis."
10/01/1997 - "Efficacy of ipratropium bromide by metered dose aerosol and aerochamber in acute paediatric bronchiolitis."
01/01/1995 - "As ipratropium bromide appears to be a more effective bronchodilator drug than beta 2-stimulants in the first year of life, a study was set up to investigate its possible role in bronchiolitis. "
11/01/1983 - "In a double blind randomised trial, we found no evidence that nebulised ipratropium bromide was of clinical benefit in acute bronchiolitis."
11/01/1999 - "Nebulised ipratropium bromide and bronchiolitis."
01/29/1996 - "Ipratropium bromide can be safely used in the management of acute bronchiolitis, recognizing that most infants do not appear to respond to any bronchodilator medication. "
|3.||Ipratropium (Ipratropium Bromide)
|8.||Cromolyn Sodium (Cromoglicic Acid)
|10.||Bronchodilator Agents (Bronchodilators)
|1.||Nebulizers and Vaporizers (Inhaler)
|2.||Metered Dose Inhalers (Metered Dose Inhaler)
|3.||Length of Stay
|4.||Dry Powder Inhalers
|5.||Gamma Cameras (Gamma Camera)